HPAPIs and Cytotoxic Drugs Manufacturing Market
- 2026 年市場規模
- USD 37.78 Bn
- 2033 年預估規模
- USD 64.81 Bn
- 年複合成長率 CAGR
- 8%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin (Chemical-based HPAPIs, Biologic-based HPAPIs), By Manufacturing Location (In-house Manufacturing, Outsourcing), By Drug Type (Novel HPAPIs, Generic HPAPIs), By Type of Pharmacological Molecule (Small Molecules, Biologics), By Application (Oncology, Respiratory, Ophthalmic Disorders, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.
Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.
Market Dynamics
Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva’s Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.
Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).
Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).
Key features of the study
• This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market
Market Segmentation
• Drug Origin Insights (Revenue, USD Bn, 2026 - 2033)
o Chemical-based HPAPIs
o Biologic-based HPAPIs
• Manufacturing Location Insights (Revenue, USD Bn, 2026 - 2033)
o In-house Manufacturing
o Outsourcing
• Drug Type Insights (Revenue, USD Bn, 2026 - 2033)
o Novel HPAPIs
o Generic HPAPIs
• Type of Pharmacological Molecule Insights (Revenue, USD Bn, 2026 - 2033)
o Small Molecules
o Biologics
• Application Insights (Revenue, USD Bn, 2026 - 2033)
o Oncology
o Respiratory
o Ophthalmic Disorders
o Others
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Teva Pharmaceutical Industries Ltd.
o Pfizer, Inc.
o Lonza Group
o CordenPharma International
o Evonik Industries AG
o Flamma Group
o Merck KGaA
o CARBOGEN AMCIS
o Catalent, Inc.
o Piramal Enterprises Ltd.
o AbbVie Inc.
o Fareva Group
o Cerbios-Pharma SA
o Novasep
o Ajinomoto Bio-Pharma
o PCI Pharma Services
o Sterling Pharma Solutions
o Heraeus Holding
o Polpharma Biologics
o Helsinn Healthcare SA
o Seqens
o Cambrex Corporation
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Origin
Market Snippet, By Manufacturing Location
Market Snippet, By Drug Type
Market Snippet, By Type of Pharmacological Molecule
Market Snippet, By Application
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Regulatory Scenario
o PEST Analysis
o Recent Product Launch/Approval
o Epidemiology
o Mergers and Acquisitions
4. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, 2026-2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Chemical-based HPAPIs
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Biologic-based HPAPIs
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
5. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location, 2026 – 2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o In-house Manufacturing
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Outsourcing
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
6. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type, 2026 – 2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Novel HPAPIs
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Generic HPAPIs
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
7. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Small Molecules
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Biologics
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
8. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application, 2026 – 2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Oncology
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Respiratory
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Ophthalmic Disorders
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
9. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region, 2026 – 2033 (USD Bn)
o Introduction
Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2021 - 2033
o North America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o U.S.
o Canada
o Latin America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Origin, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Manufacturing Location, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
Market Size and Forecast, By Type of Pharmacological Molecule, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Application, 2026 – 2033 (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033 (USD Bn)
o South Africa
o Central Africa
o North Africa
10. Competitive Landscape
o Company Profiles
Teva Pharmaceutical Industries Ltd.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Pfizer, Inc.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Lonza Group
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Corden Pharma International
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Evonik Industries AG
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Flamma Group
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Merck KGaA
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
CARBOGEN AMCIS
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Catalent, Inc.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Piramal Enterprises Ltd.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
AbbVie Inc.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Fareva Group
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Cerbios-Pharma SA
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Novasep
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Ajinomoto Bio-Pharma
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
PCI Pharma Services
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Sterling Pharma Solutions
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Heraeus Holding
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Polpharma Biologics
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Helsinn Healthcare SA
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Seqens
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Cambrex Corporation
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Analyst Views
11. Section
o References
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們